Trial Profile

An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 May 2023 The given protocol has been amended as-1)Number of treatment arms has been changed from 1 to 3.2)Status of the trial has been changed from terminated to completed.3) The sponsor of the study is Teva Branded Pharmaceutical Products R&D.4) Sequential Assignment has been included.
10 May 2023 Status changed from discontinued to completed.
31 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com